Information for Veterinary Professionals
In many canine cancers, treatment is limited by toxicity and quality-of-life considerations. CaniVax has a pipeline of tumour-specific cancer vaccines developed using its proprietary and robust platforms and tested through clinical trials.
Scientific rationale
A central challenge in veterinary oncology is achieving meaningful tumour control while maintaining tolerability over time. Many current therapies are constrained by cumulative toxicity, limiting treatment duration, intensity, or suitability for individual patients. Dog owners frequently decline the treatment because of the unpleasant side effects apparent in their pets upon treatment.
CaniVax's approach is based on identifying tumour-specific antigens and using these antigens to design vaccines that guide an antigen-specific immune response to the tumour, with the aim of improving the therapeutic outcome without the cytotoxic side effects.
Mechanism overview
CaniVax's vaccine platform is designed to link antigen discovery with clinical application through a scientifically driven process:
Tumour Antigens
Tumour-specific antigens present on cancer cells are identified through state-of-the-art technologies and platform
Ex vivo Immune Activation Testing
CaniVax's proprietary platform allows identification of immunogenic antigens that generate a robust T-cell response.
Vaccine Design and Engineering
CaniVax designs and engineers its vaccines using AI tools and proprietary algorithms, enabling the development of optimised vaccines for the patient's immune system.
Clinical Evaluation
CaniVax develops and evaluates its vaccines in patients suffering from the appropriate cancer.
Evidence and development
CaniVax vaccine programs progress through a tested and validated set of laboratory procedures that encompass translational studies in canine patients to characterise the immune response, feasibility, and safety. These results inform the design of veterinary clinical studies intended to generate evidence relevant to regulatory review and submission, and post-approval clinical practice.
Clinical trials are designed to complement existing standards-of-care and to reflect real-world treatment constraints, including tolerability and quality-of-life considerations.
Regulatory framework
CaniVax engages with relevant regulatory authorities at an early stage during development to ensure that scientific and clinical milestones align with veterinary regulatory requirements. Compassionate use of our cancer vaccines occurs under appropriate authorisation, and any future supply would require endorsement by regulatory authorities, veterinary prescription and clinical oversight.
Commercial availability is dependent on successful regulatory review and approval.
Translational strategy
CaniVax follows a structured, stepwise translational development framework that links biological discovery with clinical evaluation. Early stages focus on antigen validation and immune characterisation, followed by progressive evaluation in veterinary clinical settings under appropriate regulatory guidance and authorisation.
Development decisions are data-driven at each stage, allowing programmes to advance and be refined, reflecting emerging evidence.
Clinical evaluation context
Veterinary clinical studies are designed to characterise safety, tolerability, immune activation, and feasibility in client-owned dogs with naturally occurring disease. Study designs are intended to reflect real-world veterinary oncology practice and to generate data relevant to both regulatory review and future clinical integration.
Investigational vaccines are supplied without commercial intent during development and are administered under veterinary oversight.
Scope and current status
CaniVax programmes are investigational and under active development. Initial efforts focus on a limited number of high-incidence canine cancers where tumour biology, clinical need, and immune targeting potential align.
Scientific and clinical updates will be shared as programmes reach defined milestones.
Register your interest below:
Photo credit © Adrian Baughan - Oxford Dog Photography.